Key facts
- Ingenix raised €13 million in a funding round.
- Sofinnova Partners led the funding round.
- The funds will scale Ingenix's Modality Fusion architecture.
- Modality Fusion is an AI architecture for drug development.
- Ingenix's Biological Reasoning Engine fuses biological data.
Ingenix has announced a €13 million funding round, spearheaded by Sofinnova Partners. The company plans to utilize this capital to scale its Modality Fusion architecture, a novel system designed for AI in drug development. Ingenix's Biological Reasoning Engine employs this architecture to fuse diverse biological data. In a recent oncology project, this engine successfully completed a task in minutes that had previously required a partner biotech firm several years and millions of dollars to achieve.